Basilea Pharmaceutica AG
SIX: BSLN.SW0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Swiss Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- David Veitch
- Employees
- 164
- Headquarters
- Allschwil, Switzerland
- IPO year
- 2004
- Market cap
- CHF 668.9M
- Website
- https://www.basilea.com
Loading BSLN…
Loading profile data…Frequently asked questions about BSLN
What does Basilea Pharmaceutica AG (BSLN.SW) do?
Basilea Pharmaceutica AG, a commercial stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. It offers Cresemba, an intravenous and oral azole antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States...
Where does BSLN.SW trade?
Basilea Pharmaceutica AG (BSLN.SW) trades on the Swiss Exchange.
What sector is BSLN.SW in?
Basilea Pharmaceutica AG (BSLN.SW) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Basilea Pharmaceutica AG?
David Veitch is the chief executive officer of Basilea Pharmaceutica AG (BSLN.SW).
Where is Basilea Pharmaceutica AG headquartered?
Basilea Pharmaceutica AG is headquartered in Switzerland.
Does BSLN.SW pay a dividend?
Basilea Pharmaceutica AG (BSLN.SW) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did BSLN.SW go public?
Basilea Pharmaceutica AG (BSLN.SW) completed its initial public offering in 2004.